NCT07265544Recruiting
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 19 Jun 2025
- Start date
- 1 Mar 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- NCT number
- NCT07265544
What you commit to
- Study type: Observational
- Planned participants: 240
- From 1 Mar 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with concurrent infections such as HIV will be excluded.
Other illness
- Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included.
- Those with severe underlying diseases that affect the body's immune status will be excluded.
Other
- Individuals whom the investigator deems unsuitable for participation in this study will be excluded.
Who the study is looking for
- Voluntarily signed the informed consent form;
- No restrictions on age and gender;
- Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)";
- Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy.
Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nan Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.